

Richard Fedorak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5928115/publications.pdf>

Version: 2024-02-01

250
papers

28,348
citations

8181

76
h-index

5539

163
g-index

251
all docs

251
docs citations

251
times ranked

17517
citing authors

#	ARTICLE	IF	CITATIONS
1	Pregnancy-Related Beliefs and Concerns of Inflammatory Bowel Disease Patients Modified After Accessing e-Health Portal. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 27-35.	0.3	7
2	Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1909-1916.	1.9	34
3	Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2354-2372.	2.3	23
4	The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta. <i>PharmacoEconomics - Open</i> , 2019, 3, 591-597.	1.8	3
5	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. <i>Frontiers in Medicine</i> , 2019, 6, 170.	2.6	6
6	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	7.4	129
7	Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1515-1524.e4.	4.4	14
8	A BACH2 Gene Variant Is Associated with Postoperative Recurrence of Crohn's Disease. <i>Journal of the American College of Surgeons</i> , 2018, 226, 902-908.	0.5	9
9	Prebiotic Supplementation Following Ileocecal Resection in a Murine Model is Associated With a Loss of Microbial Diversity and Increased Inflammation. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 101-110.	1.9	10
10	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	3.7	31
11	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	4.4	41
12	A Distinctive Urinary Metabolomic Fingerprint Is Linked With Endoscopic Postoperative Disease Recurrence in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 861-870.	1.9	24
13	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 637-647.e13.	4.4	44
14	Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patients with Crohn's Disease. <i>Nutrients</i> , 2018, 10, 1761.	4.1	61
15	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 115-123.	0.3	34
16	Endospore forming bacteria may be associated with maintenance of surgically-induced remission in Crohn's disease. <i>Scientific Reports</i> , 2018, 8, 9734.	3.3	10
17	Innovative Online Educational Portal Improves Disease-Specific Reproductive Knowledge Among Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2483-2493.	1.9	18
18	Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. <i>Gut</i> , 2017, 66, 863-871.	12.1	237

#	ARTICLE	IF	CITATIONS
19	Clinical, endoscopic and radiographic outcomes with ustekinumab in medically refractory Crohn's disease: real world experience from a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1232-1243.	3.7	141
20	Biosimilars in the Treatment of Inflammatory Bowel Disease. , 2017, , 471-479.		0
21	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , 2017, 7, e016146.	1.9	35
22	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 833-839.	1.9	94
23	Clinical validation of a novel urine-based metabolomic test for the detection of colonic polyps on Chinese population. <i>International Journal of Colorectal Disease</i> , 2017, 32, 741-743.	2.2	19
24	The NOD2 -Smoking Interaction in Crohn's Disease is likely Specific to the 1007 fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. <i>EBioMedicine</i> , 2017, 21, 188-196.	6.1	20
25	Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 767-770.	1.0	17
26	Development and Validation of a High-Throughput Mass Spectrometry Based Urine Metabolomic Test for the Detection of Colonic Adenomatous Polyps. <i>Metabolites</i> , 2017, 7, 32.	2.9	30
27	Ileocolic resection is associated with increased susceptibility to injury in a murine model of colitis. <i>PLoS ONE</i> , 2017, 12, e0184660.	2.5	5
28	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. <i>World Journal of Gastroenterology</i> , 2017, 23, 3890.	3.3	28
29	Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-11.	1.9	6
30	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-9.	1.9	20
31	Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 92-99.	1.9	23
32	Ulcerative Colitis Patients With <i>Clostridium difficile</i> are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 691-704.	0.4	56
33	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1895-1902.	2.3	9
34	Urine-based metabolomic analysis of patients with <i>Clostridium difficile</i> infection: a pilot study. <i>Metabolomics</i> , 2016, 12, 1.	3.0	6
35	Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 870-879.	1.9	63
36	Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, e1-e2.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. Digestive Diseases, 2016, 34, 112-121.	1.9	7
38	A 29-year-old woman with Crohn disease considering pregnancy. Cmaj, 2016, 188, 131-132.	2.0	0
39	Patients with Active Luminal Crohn's Disease Have Evidence of Significant Functional and Clinical Pulmonary Involvement. Inflammatory Bowel Diseases, 2015, 21, 1817-1824.	1.9	3
40	Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. Journal of Clinical Gastroenterology, 2015, 49, 675-682.	2.2	41
41	Metagenomic Analysis of Microbiome in Colon Tissue from Subjects with Inflammatory Bowel Diseases Reveals Interplay of Viruses and Bacteria. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	100
42	Randomised clinical trial: vécirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 1170-1181.	3.7	86
43	Fecal Microbial Transplant After Ileocolic Resection Reduces Ileitis but Restores Colitis in IL-10 ^{-/-} Mice. Inflammatory Bowel Diseases, 2015, 21, 1479-1490.	1.9	13
44	Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	16
45	Clinicians'™ Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 369-372.	1.9	58
46	Inflammatory Bowel Disease Patients Are Frequently Nonadherent to Scheduled Induction and Maintenance Infliximab Therapy: A Canadian Cohort Study. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 309-314.	1.9	12
47	Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial. Gastroenterology, 2015, 148, 1311-1319.e6.	1.3	204
48	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. Journal of Hepatology, 2015, 63, 320-328.	3.7	170
49	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. Gastroenterology, 2015, 148, 1035-1058.e3.	1.3	323
50	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 928-935.e2.	4.4	181
51	Don't Forget the Doctor: Gastroenterologists'™ Preferences on the Development of mHealth Tools for Inflammatory Bowel Disease. JMIR MHealth and UHealth, 2015, 3, e5.	3.7	14
52	TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. World Journal of Gastroenterology, 2015, 21, 10358.	3.3	15
53	Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 181.	1.0	19
54	Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review. World Journal of Gastroenterology, 2014, 20, 4934.	3.3	95

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Highly Sensitive Urine-Based Test to Identify Patients with Colonic Adenomatous Polyps. <i>Clinical and Translational Gastroenterology</i> , 2014, 5, e54.	2.5	36
56	Disease manifestations of <i>Helicobacter pylori</i> infection in Arctic Canada: using epidemiology to address community concerns. <i>BMJ Open</i> , 2014, 4, e003689.	1.9	25
57	Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1044-1055.	3.7	40
58	The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 629-638.	3.7	88
59	Molecular Patterns in Human Ulcerative Colitis and Correlation with Response to Infliximab. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2353-2363.	1.9	20
60	Su1396 Crohn's Disease Outpatients Treated With Adalimumab Have an Earlier Loss of Response and Requirement for Dose Intensification Compared to Infliximab. <i>Gastroenterology</i> , 2014, 146, S-457-S-458.	1.3	2
61	Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2014, 146, 681-688.e1.	1.3	294
62	Real-life Treatment Paradigms Show Infliximab Is Cost-effective for Management of Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1871-1878.e8.	4.4	11
63	Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1454-1463.	1.3	43
64	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	21.4	165
65	Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 434-442.e1.	4.4	56
66	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 571-581.	1.3	66
67	Murine Ileocolic Bowel Resection with Primary Anastomosis. <i>Journal of Visualized Experiments</i> , 2014, , e52106.	0.3	3
68	Urine-based test for detection of colonic polyps: the coming of age. <i>Colorectal Cancer</i> , 2014, 3, 239-241.	0.8	0
69	Distance management of inflammatory bowel disease: Systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2014, 20, 829.	3.3	64
70	Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e42-e48.	1.3	103
71	Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature. <i>BMC Gastroenterology</i> , 2013, 13, 59.	2.0	32
72	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2013, 369, 711-721.	27.0	2,001

#	ARTICLE	IF	CITATIONS
73	Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 252-262.	3.7	167
74	Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). <i>Gastrointestinal Endoscopy</i> , 2013, 77, 624-630.	1.0	49
75	Commentary: larazotide acetate – an exciting new development for coeliac patients? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 496-497.	3.7	1
76	Celiac Disease in Children With Inflammatory Bowel Disease: a Prospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 455-456.	0.4	6
77	A Machine-Learned Predictor of Colonic Polyps Based on Urinary Metabolomics. <i>BioMed Research International</i> , 2013, 2013, 1-11.	1.9	33
78	A randomised phase I study of etrolizumab (rhuMab \hat{I}^{27}) in moderate to severe ulcerative colitis. <i>Gut</i> , 2013, 62, 1122-1130.	12.1	134
79	Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1248-1254.	3.7	40
80	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 447-459.	3.7	96
81	Epithelial Cell Extrusion Leads to Breaches in the Intestinal Epithelium. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 912-921.	1.9	23
82	Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 3347.	3.3	28
83	Prospective Study of the Quality of Colonoscopies Performed by Primary Care Physicians: The Alberta Primary Care Endoscopy (APC-Endo) Study. <i>PLoS ONE</i> , 2013, 8, e67017.	2.5	12
84	Metabolomic Profiles Are Gender, Disease and Time Specific in the Interleukin-10 Gene-Deficient Mouse Model of Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2013, 8, e67654.	2.5	17
85	Environment and the Inflammatory Bowel Diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, e18-e24.	1.7	121
86	Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e19.	2.5	40
87	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 468-481.	2.2	321
88	Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. <i>World Journal of Gastroenterology</i> , 2012, 18, 5058.	3.3	22
89	Small bowel fibrosis and systemic inflammatory response after ileocolonic anastomosis in IL-10 null mice. <i>Journal of Surgical Research</i> , 2012, 178, 147-154.	1.6	7
90	Probiotic Bacteria in the Prevention and the Treatment of Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 821-842.	2.2	21

#	ARTICLE	IF	CITATIONS
91	Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2012, 143, 1461-1469.	1.3	49
92	Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 207-214.	1.3	57
93	Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 267-275.	1.3	123
94	Risedronate improves bone mineral density in Crohn's disease: A two year randomized controlled clinical trial. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 777-786.	1.3	14
95	The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1657-1664.	2.2	53
96	Patients with Inflammatory Bowel Disease Exhibit Dysregulated Responses to Microbial DNA. <i>PLoS ONE</i> , 2012, 7, e37932.	2.5	34
97	Development and Validation of an Administrative Case Definition for Inflammatory Bowel Diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 711-717.	1.7	82
98	Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 34-40.	1.9	86
99	Intravenous Injection of Endogenous Microbial Components Abrogates DSS-Induced Colitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 345-354.	2.3	8
100	Epithelial Gaps in a Rodent Model of Inflammatory Bowel Disease: A Quantitative Validation Study. <i>Clinical and Translational Gastroenterology</i> , 2011, 2, e3.	2.5	6
101	Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 1174-1180.	1.0	70
102	A Novel Highly Sensitive Test for Detecting Colon Cancer Using Spot Urine Metabolomics. <i>Gastroenterology</i> , 2011, 140, S-40.	1.3	2
103	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , 2011, 60, 780-787.	12.1	750
104	Predicting, Treating and Preventing Postoperative Recurrence of Crohn's Disease: The State of the Field. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 140-146.	1.7	13
105	Health Care Resource Use and Costs for Crohn's Disease before and after Infliximab Therapy. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 497-502.	1.7	25
106	Patients With IBD are Exposed to High Levels of Ionizing Radiation Through CT Scan Diagnostic Imaging. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 34-39.	2.2	117
107	Mind The Gaps. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 240-245.	2.2	64
108	Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 787-797.	2.4	28

#	ARTICLE	IF	CITATIONS
109	A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 181-187.	3.7	35
110	Neonatal exposure to fecal antigens reduces intestinal inflammation. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 899-906.	1.9	5
111	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD. , 2011, , 123-150.		2
112	Oral Administration of Curcumin Emulsified in Carboxymethyl Cellulose Has a Potent Anti-inflammatory Effect in the IL-10 Gene-Deficient Mouse Model of IBD. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1272-1277.	2.3	55
113	Naturally Occurring Glycoalkaloids in Potatoes Aggravate Intestinal Inflammation in Two Mouse Models of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3078-3085.	2.3	28
114	Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1209-1218.	1.9	82
115	Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 522-528.	3.7	95
116	Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1129-1134.	3.7	81
117	An imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animal's first exposure to faecal bacteria and antigens. <i>Clinical and Experimental Immunology</i> , 2010, 161, 187-196.	2.6	17
118	A Randomized Trial of Topical Anesthesia Comparing Lidocaine Versus Lidocaine Plus Xylometazoline for Unsedated Transnasal Upper Gastrointestinal Endoscopy. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 317-321.	1.7	16
119	Canadian Digestive Health Foundation Public Impact Series. Inflammatory Bowel Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 651-655.	1.7	21
120	Tumor Necrosis Factor- α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 543-557.	2.2	39
121	Metabolomics and detection of colorectal cancer in humans: a systematic review. <i>Future Oncology</i> , 2010, 6, 1395-1406.	2.4	90
122	Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 44-49.	1.0	81
123	S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2010, 138, S-167-S-168.	1.3	15
124	Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 688-695.e2.	4.4	142
125	Probiotics in the management of ulcerative colitis. <i>Gastroenterology and Hepatology</i> , 2010, 6, 688-90.	0.1	10
126	Long-Term Response Rates to Infliximab Therapy for Crohn's Disease in an Outpatient Cohort. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009, 23, 348-352.	1.7	36

#	ARTICLE	IF	CITATIONS
127	Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn's Disease. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 185-202.	1.7	37
128	Does Smoking Reduce Infliximab's Effectiveness against Crohn's Disease?. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 121-125.	1.7	18
129	Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut, 2009, 58, 1354-1362.	12.1	49
130	Effect of Lactobacillus plantarum 299v treatment in an animal model of irritable bowel syndrome. Microbial Ecology in Health and Disease, 2009, 21, 33-37.	3.5	6
131	Bacterial Overgrowth and Inflammation of Small Intestine After Carboxymethylcellulose Ingestion in Genetically Susceptible Mice. Inflammatory Bowel Diseases, 2009, 15, 359-364.	1.9	141
132	Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. Inflammatory Bowel Diseases, 2009, 15, 760-768.	1.9	119
133	Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 1599-1604.	1.9	93
134	Pneumococcal Pneumonia: Potential for Diagnosis through a Urinary Metabolic Profile. Journal of Proteome Research, 2009, 8, 5550-5558.	3.7	93
135	Probiotics in Ulcerative Colitis. , 2009, , 181-194.		0
136	CD4+CD25+ Regulatory T Cells Have Divergent Effects on Intestinal Inflammation in IL-10 Gene-Deficient Mice. Digestive Diseases and Sciences, 2008, 53, 1544-1552.	2.3	0
137	Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF α , improves health-related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease, 2008, 23, 289-296.	2.2	51
138	A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease. Gastroenterology, 2008, 135, 1130-1141.	1.3	709
139	Allopurinol to Prevent Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Randomized Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology, 2008, 6, 465-471.	4.4	29
140	Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the $\alpha_4\beta_7$ Integrin. Clinical Gastroenterology and Hepatology, 2008, 6, 1370-1377.	4.4	283
141	Urinary Metabolic Profiles of Inflammatory Bowel Disease in Interleukin-10 Gene-Deficient Mice. Analytical Chemistry, 2008, 80, 5524-5531.	6.5	70
142	Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent?. Journal of Medical Microbiology, 2008, 57, 111-117.	1.8	24
143	Understanding Why Probiotic Therapies Can be Effective in Treating IBD. Journal of Clinical Gastroenterology, 2008, 42, S111-S115.	2.2	40
144	Recommendations for Probiotic Use—2008. Journal of Clinical Gastroenterology, 2008, 42, S104-S108.	2.2	120

#	ARTICLE	IF	CITATIONS
145	Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 261-272.	1.7	10
146	<i>Helicobacter Pylori</i> Infection in Canada's Arctic: Searching for the Solutions. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 912-916.	1.7	19
147	VSL#3 Probiotic Upregulates Intestinal Mucosal Alkaline Sphingomyelinase and Reduces Inflammation. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 237-242.	1.7	69
148	Exercise and Inflammatory Bowel Disease. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 497-504.	1.7	65
149	Early Experience with Unsedated Ultrathin 4.9 mm Transnasal Gastroscopy: A Pilot Study. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 917-922.	1.7	9
150	Canadian Digestive Health Foundation: Interview with the New President, Dr Richard Fedorak. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 345-346.	1.7	1
151	Oropharyngeal Crohn's disease. Clinical and Experimental Gastroenterology, 2008, 1, 15.	2.3	9
152	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut, 2007, 56, 1232-1239.	12.1	866
153	Probiotics in the Management of Inflammatory Bowel Diseases?. American Journal of Gastroenterology, 2007, 102, S22-S28.	0.4	4
154	Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. American Journal of Clinical Nutrition, 2007, 85, 816-823.	4.7	153
155	Vertebral Fractures and Role of Low Bone Mineral Density in Crohn's Disease. Clinical Gastroenterology and Hepatology, 2007, 5, 721-728.	4.4	46
156	Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial. Gastroenterology, 2007, 132, 1672-1683.	1.3	586
157	American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21-23, 2006. Gastroenterology, 2007, 133, 312-339.	1.3	197
158	Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse. Inflammatory Bowel Diseases, 2007, 13, 947-954.	1.9	35
159	The role of probiotics in management of irritable bowel syndrome. Current Gastroenterology Reports, 2007, 9, 393-400.	2.5	15
160	Probiotics in the Management of Inflammatory Bowel Diseases?. American Journal of Gastroenterology, 2007, 102, 22-28.	0.4	0
161	Probiotic Therapies for IBD. Gastroenterology and Hepatology, 2007, 3, 180-1.	0.1	0
162	Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn's Disease: the CLASSIC-I Trial. Gastroenterology, 2006, 130, 323-333.	1.3	1,523

#	ARTICLE	IF	CITATIONS
163	Onercept for Moderate-to-Severe Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 888-893.	4.4	65
164	Probiotics in the Treatment of Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 260-263.	2.2	78
165	Recommendations for Probiotic Use. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 275-278.	2.2	56
166	Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 429-436.	1.9	15
167	A defect in epithelial barrier integrity is not required for a systemic response to bacterial antigens or intestinal injury in T cell receptor- α gene-deficient mice. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 750-757.	1.9	9
168	The role of antibiotic and probiotic therapies in current and future management of inflammatory Bowel disease. <i>Current Gastroenterology Reports</i> , 2006, 8, 486-498.	2.5	37
169	The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2006, 101, 1559-1568.	0.4	522
170	The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. <i>Journal of Medical Microbiology</i> , 2006, 55, 1141-1149.	1.8	211
171	Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 303-316.	13.7	82
172	Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 765-777.	1.9	48
173	Association with Selected Bacteria Does Not Cause Enterocolitis in IL-10 Gene-Deficient Mice Despite a Systemic Immune Response. <i>Digestive Diseases and Sciences</i> , 2005, 50, 905-913.	2.3	29
174	Effects of Formal Education for Patients with Inflammatory Bowel Disease: A Randomized Controlled Trial. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005, 19, 235-244.	1.7	121
175	VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2005, 100, 1539-1546.	0.4	659
176	Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 122-132.	4.4	78
177	Treatment of Ulcerative Colitis with a Humanized Antibody to the $\alpha_4\beta_7$ Integrin. <i>New England Journal of Medicine</i> , 2005, 352, 2499-2507.	27.0	736
178	The Role of Enteric Microflora in Inflammatory Bowel Disease: Human and Animal Studies with Probiotics and Prebiotics. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 465-482.	2.2	51
179	Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. <i>Current Opinion in Pharmacology</i> , 2005, 5, 596-603.	3.5	112
180	A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2005, 129, 807-818.	1.3	571

#	ARTICLE	IF	CITATIONS
181	Probiotics in the management of inflammatory bowel disease. MedGenMed: Medscape General Medicine, 2005, 7, 19.	0.2	2
182	Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 503-508.	1.7	25
183	Endoscopic Perforation Rates at a Canadian University Teaching Hospital. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 221-226.	1.7	56
184	Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. New England Journal of Medicine, 2004, 350, 876-885.	27.0	2,026
185	Bones and Crohn's. Inflammatory Bowel Diseases, 2004, 10, 220-228.	1.9	71
186	Probiotics and the Management of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 286-299.	1.9	155
187	Is it time to re-classify Crohn's disease?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 99-106.	2.4	11
188	Conservative approach to severe ulcerative colitis. Digestive and Liver Disease, 2004, 36, 4-6.	0.9	1
189	Probiotics and prebiotics in gastrointestinal disorders. Current Opinion in Gastroenterology, 2004, 20, 146-155.	2.3	108
190	Lack of Interleukin-10 Leads to Intestinal Inflammation, Independent of the Time at Which Luminal Microbial Colonization Occurs. Inflammatory Bowel Diseases, 2003, 9, 87-97.	1.9	57
191	VSL3 probiotic mixture induces remission in patients with active ulcerative colitis. Gastroenterology, 2003, 124, A377.	1.3	28
192	The Frequency of Vitamin D Deficiency in Adults with Crohn's Disease. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 473-478.	1.7	91
193	Potato Glycoalkaloids Adversely Affect Intestinal Permeability and Aggravate Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2002, 8, 340-346.	1.9	84
194	Normal Breast Milk Limits the Development of Colitis in IL-10 Deficient Mice. Inflammatory Bowel Diseases, 2002, 8, 390-398.	1.9	31
195	A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. New England Journal of Medicine, 2000, 342, 1627-1632.	27.0	704
196	An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology, 2000, 118, A874.	1.3	81
197	Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology, 2000, 119, 1461-1472.	1.3	442
198	Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology, 2000, 119, 1473-1482.	1.3	490

#	ARTICLE	IF	CITATIONS
199	Antibiotic therapy attenuates colitis in interleukin 10 geneâ€“deficient mice. Gastroenterology, 2000, 118, 1094-1105.	1.3	215
200	Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. Alimentary Pharmacology and Therapeutics, 1999, 13, 1565-1584.	3.7	86
201	Lactobacillus species prevents colitis in interleukin 10 geneâ€“deficient mice. Gastroenterology, 1999, 116, 1107-1114.	1.3	710
202	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology, 1999, 117, 527-535.	1.3	236
203	Interleukin-10 Gene-Deficient Mice Develop a Primary Intestinal Permeability Defect in Response to Enteric Microflora. Inflammatory Bowel Diseases, 1999, 5, 262-270.	1.9	259
204	Endogenous Interleukin-10 Regulates Hemodynamic Parameters, Leukocyte-Endothelial Cell Interactions, and Microvascular Permeability During Endotoxemia. Circulation Research, 1998, 83, 1124-1131.	4.5	73
205	Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology, 1997, 113, 383-389.	1.3	484
206	Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion. Gastroenterology, 1997, 113, 151-159.	1.3	161
207	A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology, 1997, 112, 1069-1077.	1.3	170
208	Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats. , 1997, 18, 681-695.		8
209	Small Intestinal Function Following Syngeneic Transplantation in the Rat. Journal of Surgical Research, 1996, 61, 379-384.	1.6	28
210	Increased permeability occurs in rat ileum following induction of pancolitis. Digestive Diseases and Sciences, 1996, 41, 405-411.	2.3	13
211	Nutritional and intestinal effects of the novel immunosuppressive agents: Deoxyspergualin, rapamycin, and mycophenolate mofetil. Clinical Biochemistry, 1996, 29, 363-369.	1.9	15
212	TACROLIMUS (FK506)-ITS EFFECTS ON INTESTINAL GLUCOSE TRANSPORT1. Transplantation, 1996, 61, 630-634.	1.0	24
213	Insulin downregulates diabetic-enhanced intestinal glucose transport rapidly in ileum and slowly in jejunum. Canadian Journal of Physiology and Pharmacology, 1996, 74, 1294-1301.	1.4	5
214	Budesonideâ€“â€“glucuronide: A Potential Prodrug for Treatment of Ulcerative Colitis. Journal of Pharmaceutical Sciences, 1995, 84, 677-681.	3.3	23
215	Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine. Diabetologia, 1995, 38, 403-412.	6.3	23
216	A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. American Journal of Physiology - Renal Physiology, 1995, 269, G210-G218.	3.4	1

#	ARTICLE	IF	CITATIONS
217	Methotrexate for the Treatment of Crohn's Disease. New England Journal of Medicine, 1995, 332, 292-297.	27.0	920
218	Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression. Gastroenterology, 1995, 108, 1688-1699.	1.3	38
219	FK506 increases permeability in rat intestine by inhibiting mitochondrial function. Gastroenterology, 1995, 109, 107-114.	1.3	75
220	The buried gastrostomy bumper syndrome: prevention and endoscopic approaches to removal. Gastrointestinal Endoscopy, 1995, 41, 505-508.	1.0	89
221	Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine. Diabetologia, 1995, 38, 403-412.	6.3	0
222	A budesonide prodrug accelerates treatment of colitis in rats.. Gut, 1994, 35, 1439-1446.	12.1	48
223	Low-Dose Cyclosporine for the Treatment of Crohn's Disease. New England Journal of Medicine, 1994, 330, 1846-1851.	27.0	256
224	Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology, 1994, 106, 287-296.	1.3	688
225	A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. Gastroenterology, 1994, 106, 405-413.	1.3	40
226	Acetic acid-induced colitis results in bystander ileal injury. Agents and Actions, 1993, 38, 76-84.	0.7	10
227	Jejunum is preferable for construction of a bianchi bowel-lengthening procedure in swine short bowel. Journal of Pediatric Surgery, 1993, 28, 102-109.	1.6	12
228	Oral Vanadate Reduces Na ⁺ -Dependent Glucose Transport in Rat Small Intestine. Diabetes, 1993, 42, 1126-1132.	0.6	20
229	INTESTINAL FUNCTION FOLLOWING ALLOGENEIC SMALL INTESTINAL TRANSPLANTATION IN THE RAT. Transplantation, 1992, 53, 264-271.	1.0	38
230	Food consistency effects of quarg in lactose malabsorption. International Dairy Journal, 1992, 2, 257-269.	3.0	20
231	Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerates healing. Prostaglandins Leukotrienes and Essential Fatty Acids, 1992, 45, 275-281.	2.2	11
232	Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in rats. Digestive Diseases and Sciences, 1992, 37, 205-214.	2.3	79
233	Verapamil alters eicosanoid synthesis and accelerates healing during experimental colitis in rats. Gastroenterology, 1992, 102, 1229-35.	1.3	7
234	Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in rats. Canadian Journal of Physiology and Pharmacology, 1991, 69, 480-487.	1.4	52

#	ARTICLE	IF	CITATIONS
235	Adaptation of intestinal glucose transport in rats with diabetes mellitus occurs independent of hyperphagia. Canadian Journal of Physiology and Pharmacology, 1991, 69, 1143-1148.	1.4	16
236	Diabetes Mellitus and Glucagon Alter Ouabain-Sensitive Na ⁺ -K ⁺ -ATPase in Rat Small Intestine. Diabetes, 1991, 40, 1603-1610.	0.6	14
237	Altered glucose carrier expression: mechanism of intestinal adaptation during streptozocin-induced diabetes in rats. American Journal of Physiology - Renal Physiology, 1991, 261, G585-G591.	3.4	42
238	Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology, 1990, 98, 615-625.	1.3	141
239	The physiology of adaptation to small bowel resection in the pig: An integrated study of morphological and functional changes. Journal of Pediatric Surgery, 1990, 25, 650-657.	1.6	53
240	Effect of somatostatin analog (SMS 201-995) on in vivo intestinal fluid transport in rats. Digestive Diseases and Sciences, 1989, 34, 567-572.	2.3	13
241	Effect of misoprostol in preventing stress-induced intestinal fluid secretion in rats. Prostaglandins Leukotrienes and Essential Fatty Acids, 1989, 38, 43-48.	2.2	19
242	Inhibition of Cholera-Toxin-Stimulated Intestinal Secretion by CGS 9343B in Rats. Journal of Pediatric Gastroenterology and Nutrition, 1989, 8, 252-258.	1.8	4
243	In vitro effects of the long-acting somatostatin analogue SMS 201-995 on electrolyte transport by the rabbit ileum. Gastroenterology, 1988, 94, 1343-1350.	1.3	26
244	Antidiarrheal therapy. Digestive Diseases and Sciences, 1987, 32, 195-205.	2.3	24
245	Intestinal adaptation to diabetes. Altered Na-dependent nutrient absorption in streptozocin-treated chronically diabetic rats. Journal of Clinical Investigation, 1987, 79, 1571-1578.	8.2	60
246	Experimental diabetic diarrhea in rats. Gastroenterology, 1986, 91, 564-569.	1.3	62
247	Experimental diabetic diarrhea in rats. Intestinal mucosal denervation hypersensitivity and treatment with clonidine. Gastroenterology, 1986, 91, 564-9.	1.3	19
248	Treatment of Diabetic Diarrhea with Clonidine. Annals of Internal Medicine, 1985, 102, 197.	3.9	170
249	Short Bowel Syndrome. , 0, , 1295-1321.		0
250	Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflammatory Bowel Diseases, 0, 5, 262-270.	1.9	30